Study Highlights Long-Lasting Effectiveness Of Full COVID-19 mRNA Vaccination Course

Pharmacy Times (4/23) reports that “following a full 3-dose mRNA vaccination against SARS-CoV-2, the virus that causes COVID-19, health care workers with distinct exposure histories developed durable, sustained B-cell and antibody responses over a 3-year period, with participants retaining a significant SARS-CoV-2-reactive memory B-cell (MBC) pool that prevented breakthrough infections in naïve participants.” Researchers found that “breakthrough infections post-vaccination increased receptor-binding domain memory B-cell frequencies, shaping the humoral response in non-exposed subjects.” Data also suggest that “previously infected individuals developed stable atypical B-cell populations, with comparable humoral responses 17 months after full vaccination.” Researchers noted that “long-term studies of mRNA vaccine effectiveness are crucial for guiding vaccine recommendations amid emerging variants.” The study was published in Cell Reports.